163 related articles for article (PubMed ID: 16848745)
41. Chalcones are potent inhibitors of aromatase and 17beta-hydroxysteroid dehydrogenase activities.
Le Bail JC; Pouget C; Fagnere C; Basly JP; Chulia AJ; Habrioux G
Life Sci; 2001 Jan; 68(7):751-61. PubMed ID: 11205867
[TBL] [Abstract][Full Text] [Related]
42. Biochemical and biological evaluation of novel potent coumarin inhibitor of 17β-HSD type 1.
Starčević S; Kocbek P; Hribar G; Rižner TL; Gobec S
Chem Biol Interact; 2011 May; 191(1-3):60-5. PubMed ID: 21232530
[TBL] [Abstract][Full Text] [Related]
43. Synthesis and preliminary evaluation of a modified estradiol-core bearing a fused γ-lactone as non-estrogenic inhibitor of 17β-hydroxysteroid dehydrogenase type 1.
Ouellet E; Ayan D; Poirier D
Bioorg Med Chem Lett; 2011 Sep; 21(18):5510-3. PubMed ID: 21782424
[TBL] [Abstract][Full Text] [Related]
44. A 6beta-(thiaheptanamide) derivative of estradiol as inhibitor of 17beta-hydroxysteroid dehydrogenase type 1.
Poirier D; Dionne P; Auger S
J Steroid Biochem Mol Biol; 1998 Jan; 64(1-2):83-90. PubMed ID: 9569013
[TBL] [Abstract][Full Text] [Related]
45. Biological activity of pyrazole and imidazole-dehydroepiandrosterone derivatives on the activity of 17β-hydroxysteroid dehydrogenase.
Cabeza M; Posada A; Sánchez-Márquez A; Heuze Y; Moreno I; Soriano J; Garrido M; Cortés F; Bratoeff E
J Enzyme Inhib Med Chem; 2016; 31(1):53-62. PubMed ID: 25690043
[TBL] [Abstract][Full Text] [Related]
46. Chemical synthesis of C3-oxiranyl/oxiranylmethyl-estrane derivatives targeted by molecular modeling and tested as potential inhibitors of 17β-hydroxysteroid dehydrogenase type 1.
Lespérance M; Barbeau X; Roy J; Maltais R; Lagüe P; Poirier D
Steroids; 2018 Dec; 140():104-113. PubMed ID: 30273695
[TBL] [Abstract][Full Text] [Related]
47. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
[TBL] [Abstract][Full Text] [Related]
48. Synthesis of substituted 15β-alkoxy estrone derivatives and their cofactor-dependent inhibitory effect on 17β-HSD1.
Herman BE; Kiss A; Wölfling J; Mernyák E; Szécsi M; Schneider G
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1271-1286. PubMed ID: 31307240
[TBL] [Abstract][Full Text] [Related]
49. Aromatase and 17beta-hydroxysteroid dehydrogenase inhibition by flavonoids.
Le Bail JC; Laroche T; Marre-Fournier F; Habrioux G
Cancer Lett; 1998 Nov; 133(1):101-6. PubMed ID: 9929167
[TBL] [Abstract][Full Text] [Related]
50. Synthesis of a dansyl-labeled inhibitor of 17β-hydroxysteroid dehydrogenase type 3 for optical imaging.
Kenmogne LC; Maltais R; Poirier D
Bioorg Med Chem Lett; 2016 May; 26(9):2179-83. PubMed ID: 27025340
[TBL] [Abstract][Full Text] [Related]
51. Proliferative effect of androst-4-ene-3,17-dione and its metabolites in the androgen-sensitive LNCaP cell line.
Laplante Y; Poirier D
Steroids; 2008 Mar; 73(3):266-71. PubMed ID: 18082864
[TBL] [Abstract][Full Text] [Related]
52. STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.
Day JM; Foster PA; Tutill HJ; Schmidlin F; Sharland CM; Hargrave JD; Vicker N; Potter BV; Reed MJ; Purohit A
Endocr Relat Cancer; 2013 Feb; 20(1):53-64. PubMed ID: 23132791
[TBL] [Abstract][Full Text] [Related]
53. Preparation of 6beta-estradiol derivative libraries as bisubstrate inhibitors of 7beta-hydroxysteroid dehydrogenase type using the multidetachable sulfamate linker.
Bérubé M; Delagoutte F; Poirier D
Molecules; 2010 Mar; 15(3):1590-631. PubMed ID: 20336003
[TBL] [Abstract][Full Text] [Related]
54. Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry.
El-Alfy M; Luu-The V; Huang XF; Berger L; Labrie F; Pelletier G
Endocrinology; 1999 Mar; 140(3):1481-91. PubMed ID: 10067877
[TBL] [Abstract][Full Text] [Related]
55. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
[TBL] [Abstract][Full Text] [Related]
56. Design, chemical synthesis and biological evaluation of 3-spiromorpholinone/3-spirocarbamate androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
Djigoué GB; Kenmogne LC; Roy J; Maltais R; Poirier D
Bioorg Med Chem; 2015 Sep; 23(17):5433-51. PubMed ID: 26277760
[TBL] [Abstract][Full Text] [Related]
57. Phytoestrogens inhibit aromatase but not 17beta-hydroxysteroid dehydrogenase (HSD) type 1 in human granulosa-luteal cells: evidence for FSH induction of 17beta-HSD.
Whitehead SA; Lacey M
Hum Reprod; 2003 Mar; 18(3):487-94. PubMed ID: 12615812
[TBL] [Abstract][Full Text] [Related]
58. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a series of 4-hydroxyphenyl ketones as potential inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3).
Lota RK; Dhanani S; Owen CP; Ahmed S
Bioorg Med Chem Lett; 2006 Sep; 16(17):4519-22. PubMed ID: 16797984
[TBL] [Abstract][Full Text] [Related]
59. The UV-filter benzophenone-1 inhibits 17beta-hydroxysteroid dehydrogenase type 3: Virtual screening as a strategy to identify potential endocrine disrupting chemicals.
Nashev LG; Schuster D; Laggner C; Sodha S; Langer T; Wolber G; Odermatt A
Biochem Pharmacol; 2010 Apr; 79(8):1189-99. PubMed ID: 20005209
[TBL] [Abstract][Full Text] [Related]
60. Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation.
Abdelsamie AS; Salah M; Siebenbürger L; Hamed MM; Börger C; van Koppen CJ; Frotscher M; Hartmann RW
Eur J Med Chem; 2019 Sep; 178():93-107. PubMed ID: 31176098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
